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1 
COMPOSITIONS AND METHODS FOR 
TREATING RETINAL DEGRADATION 
RELATED APPLICATIONS 
2 
prising administering an effective amount of a composition to 
a subject in need thereof, wherein the composition comprises 
a reverse transcriptase inhibitor, such as a nucleoside reverse 
transcriptase inhibitor (NRTI), selected from: (i) a compound 
5 having the structure of 
This application claims priority from U.S. Provisional 
Application Ser. No. 61/861,290, filed Aug. 1, 2013, and from 
U.S. Provisional Application Ser. No. 61/987,612, filed May 
2, 2014, the entire disclosures of which are incorporated 
herein by this reference. 
TECHNICAL FIELD 
10 
0 
H;C'C~ 
NAO 
0:9 
I 
H3C 
The presently-disclosed subject matter relates to composi-
tions for treating retinal damage and/or degradation. More 15 
specifically, this disclosure relates to methods for treating 
degradation of the retinal pigment epithelium by administer-
ing compositions comprising a nucleoside and/or a nucleo-
side reverse transcriptase inhibitor (NRTI). or a pharmaceutically acceptable salt thereof; 
20 (ii) a compound having the structure of 
BACKGROUND 
Geographic atrophy, an advanced form of age-related 
macular degeneration that causes blindness in millions of 
people worldwide and for which there is no approved treat- 25 
ment, results from death of retinal pigmented epithelium 
(RPE) cells. For example, expression ofDICER, an enzyme 
involvedinmicroRNA (miRNA) biogenesis, is reduced in the 
RPE of human eyes with geographic atrophy, and that condi-
tional ablation ofDicerl induces RPE degeneration in mice. 30 
Surprisingly, ablation of seven other enzymes responsible for 
miRNA biogenesis or function does not induce such pathol-
ogy. Instead, knockdown of DICERl leads to accumulation 
of Alu repeat RNA in human RPE cells and of Bl and B2 
(Alu-like elements) repeat RNAs in the RPE of mice. Alu 35 
RNA is dramatically increased in the RPE ofhuman eyes with 
geographic atrophy, and introduction of this pathological 
RNA induces death of human RPE cells and RPE degenera-
tion in mice. 
Age-related macular degeneration (AMD), which is as 40 
prevalent as cancer in industrialized countries, is a leading 
cause of blindness worldwide. In contrast to the neovascular 
form of AMD, for which many approved treatments exist, the 
far more common atrophic form of AMD remains poorly 
understood and without effective clinical intervention. Ext en- 45 
sive atrophy of the retinal pigment epithelium leads to severe 
vision loss and is termed geographic atrophy. 
o:'f Ls 
~· 
\ 
0 
\ 
CH3 
or a pharmaceutically acceptable salt thereof; (iii) stavudine 
(d4T); (iv) lamivudine (3TC); (v) cordycepin; (vi) azidothy-
midine (AZT); (vii) abacavir (ABC); and/or (viii) a combi-
nation thereof. 
Moreover, the methods of the present disclosure may fur-
ther comprise the steps of (i) inhibiting inflammasome acti-
vation by Alu RNA; (ii) reducing ATP-induced permeability 
of a cell; (iii) reducing an amount of mitochondrial reactive 
oxygen species in a cell; and/or (iv) inhibiting activation of at 
least one inflammasome in a subject's eye. Additionally, the 
cell(s) of the methods of the present disclosure may be cho-
sen, for example, from a retinal pigmented epithelium cell, a 
retinal photoreceptor cell, a choroidal cell, and a combination 
thereof. And an inflammasome of the present disclosure may 
be, for example, an NLRP3 inflammasome, an IL-l beta 
Hence, there remains a need for compositions and methods 
for treating retinal degradation, and particularly RPE degra-
dation. 50 inflammasome, or a combination thereof. 
BRIEF SUMMARY 
This summary describes several embodiments of the pres-
ently-disclosed subject matter, and in many cases lists varia- 55 
tions and permutations of these embodiments. This s=ary 
is merely exemplary of the numerous and varied embodi-
ments. Mention of one or more representative features of a 
given embodiment is likewise exemplary. Such an embodi-
ment can typically exist with or without the feature(s) men- 60 
tioned; likewise, those features can be applied to other 
embodiments of the presently-disclosed subject matter, 
whether listed in this summary or not. To avoid excessive 
repetition, this summary does not list or suggest all possible 
combinations of features. 65 
The present disclosure provides, in certain embodiments, a 
method for treating retinal damage and/or degradation, com-
Furthermore, in some embodiments, the present disclosure 
provides a compound having the structure: 
US 9,326,983 B2 
3 
or a pharmaceutically acceptable salt thereof; 
or a compound having the structure 
or a pharmaceutically acceptable sale thereof. 
4 
FIG. 6 is a Western blot showing that Alu RNA causes 
Caspase-1 maturation in primary human RPE cells at 24 
hours after Alu administration (top, middle lane, lower band), 
which is blocked with co-treatment with 3TC (20-100 uM; 
5 rightmost lane), wherein the lowermost band is the loading 
control, vinculin. 
FIG. 7 is a Western blot showing that Alu RNA causes 
Caspase-1 maturation in primary human RPE cells at 24 
hours after Alu administration (top, middle lane, lower band), 
10 
which is blocked with co-treatment with azidothymidine 
(AZT), cordycepin, and abacavir (ABC) (50-100 uM; lanes 
3-8 from left). The loading control vinculin is shown on the 
bottom. 
15 FIG. 8 provides a gel showing that primary human RPE 
cells treated with LPS/ ATP, a classic inflammasome activator, 
exhibit increased Casp-1 activation, and phosphorylation of 
IRAK4, which is also a marker of inflammasome signaling 
via the cell surface receptor adaptor protein MyD88. More-
20 over, as shown in FIG. 8, d4T (25/100 uM) blocks Casp-1 
activation and IRAK 4 phosphorylation induced by LPS/ ATP. 
Vinculin was used as the loading control in the gel of FIG. 8. 
Additionally, as shown, LPS and ATP activate the NLRP3 
The present disclosure also provides a pharmaceutical 
composition comprising at least one of the compounds pro-
vided in the present disclosure, together with a pharmaceuti-
cally acceptable carrier. And further embodiments of the 25 
present disclosure include a method for synthesizing at least 
one compound provided in the present disclosure. 
inflammasome only in combination. 
FIG. 9 provides the results of Western blotting, wherein 
d4T, 3TC, and cordycepin (at 100 uM), all di-deoxy nucleo-
side reverse transcriptase inhibitors, are shown to inhibit 
Caspase-1 activation (active p20 band, top) and IL-18 matu-
ration (bottom) induced by LPS/ATP. To produce FIG. 9, cell BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 displays a top row of ocular fundus photographs of 
mice receiving control PBS, or Alu RNA treatment, with or 
without increasing amounts of d4 T (left to right); and RPE flat 
mounts, stained for intercellular junctions (Z0-1) in red that 
are disrupted upon Alu RNA administration but that are 
restored to healthy RPE morphology/intercellular junctions 
at highest dose of d4 T. 
FIG. 2 provides a bar graph showing that human (HeLa) 
cells treated with an enforced expression plasmid for Alu 
RNA (pAluA) for denoted amounts of time exhibited pro-
foundly reduced viability compared to a null plasmid 
(pUC19), as monitored by MTS proliferation assay and that 
d4T co-administration prevented cell death induced by Alu 
overexpression. 
FIG. 3 shows the results of Northern blotting using an 
Alu-specific probe. As presented in FIG. 3, primary human 
RPE cells treated with antisense oligonucleotides targeting 
DICERl (Dcr as) (lane 3 (third lane from left)) show 
increasedAlu RNA levels in the nuclear compartment com-
pared to control antisense oligonucleotides (Ctr as) (lane 1 
(leftmost)), and co-administration of d4 T (lanes 2 and 4) does 
not reduce Alu RNA levels. u6 (bottom row) is shown as a 
loading control for nuclear fraction. 
FIG. 4 provides another example of the results ofNorthern 
blotting using an Alu-specific probe. As presented in FIG. 4, 
co-administration of d4 T does not change Alu RNA levels at 
30 culture supernatants were collected after (i) no treatment, (ii) 
LPS treatment, or (iii) LPS/ATP treatment of mouse bone 
marrow-derived macrophages and run on Western blotting 
probing with antibodies for Caspase-1 and IL-18. 
FIG. 10 provides the result of a Western blot showing that 
35 d4T (1 00, 250 uM) inhibits IL-l beta maturation (top, 18 and 
22 kDa forms) and Caspase-1 activation (active p20 band, 
bottom) induced by nigericin. To produce FIG. 10, cell cul-
ture supernatants were collected after (i) no treatment, (ii) 
LPS treatment, or (iii) LPS/nigericin treatment of mouse bone 
40 marrow-derived macrophages and run on Western blotting 
probing with antibodies for IL-l beta and Caspase-1. 
FIG. 11 shows a bar graph illustrating that d4T does not 
inhibit IL-l beta secretion from PMA-differentiated THP-1 
monocytes induced by monosodium urate (MSU). FIG. 11 
45 was created after human THP-1 monocytes were differenti-
ated into macrophages with PMA, and, as shown in FIG. 11, 
treatment with MSU, a known inflammasome activator, 
increased IL-l beta secretion compared to non-treated cells, 
whereas d4T co-administration at a range of doses (25-1000 
so uM) did not significantly affect IL-l beta secretion. 
FIG. 12 is a bar graph, which shows that d4T and other 
nucleoside reverse transcriptase inhibitors do not inhibit IL-l 
beta secretion from PMA-differentiated THP-1 monocytes 
induced by MSU. Human THP-1 monocytes were differenti-
55 a ted into macrophages with PMA. Their treatment with MSU 
increased IL-l beta secretion compared to non-treated cells, 
as shown in FIG. 12, while co-administration of d4T, 3TC, or 
cordycepin (all are di -deoxy nucleotide analogs) at a range of 
1, 4, or 24 hours after transfection in the nuclear fraction of 
human RPE cells transfected with Alu RNA, with or without 
d4T, as detected by Northern blotting using an Alu-specific 
probe. u6 (bottom row) is shown as loading control for 60 
nuclear fraction in FIG. 4. 
doses (25-1 000 uM) did not significantly affect IL-beta secre-
tion. 
FIG. 13 is a graph, which provides that d4T reduces 
NLRP3 priming induced by Alu RNA. Indeed, as shown in 
FIG. 13, Alu RNA transfection increases NLRP3 mRNA 
levels in primary human RPE cells at 16 hours, an event 
termed "priming" (Y-axis) compared to mock (transfection 
reagent alone). This effect is blunted by co-administration of 
FIG. 5 provides the results of a Western blot showing that 
Alu RNA causes Caspase-1 maturation in primary human 
RPE cells at 24 hours after Alu administration (top, middle 
lane, lower band), which is blocked by co-treatment with d4T 65 
(100 uM; rightmost lane). The bottom row is a vinculin load-
ing control. d4T (1 00 uM) and normalized to ISS RNA control. 
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FIG. 14 illustrates, in graph format, that Alu RNA trans-
fection increases IL-l beta mRNA levels in primary human 
RPE cells at 24 hours, an event termed "priming", (Y-axis) 
compared to mock (transfection reagent alone). This effect is 
blunted by co-administration of d4T (100 uM) and normal- 5 
ized to ISS RNA control. 
FIG.15 shows that d4T reduces mitochondrial ROS caused 
6 
FIG. 25 provides a schematic overview ofme-d4T synthe-
SIS. 
FIG. 26 is an HPLC chromatogram ofme-d4T (peak #6) 
final product, >97% purity. 
FIG. 27 is a lH NMR spectroscopy ofme-d4T final prod-
uct, wherein the chemical shifts are consistent with the struc-
ture ofme-d4T. 
FIG. 28 provides the results of liquid chromatography/ 
mass spectrometry of me-d4T final product, m/z ratio consis-
10 tent with the structure ofme-d4T. 
by Alu expression. Indeed, FIG. 15 demonstrates that 
enforced expression of Alu (pA!uA) causes increased mito-
chondrial reactive oxygen species (mtROS), as detected by 
MitoSox assay. In order to produce FIG. 15, primary human 
RPE cells were incubated with Alu expressing plasmid or 
control plasmid (p UC19) with or without d4 T. After 15 hours 
cells were co-stained for mtROS (red) and for cell count, 
nuclei (blue; Hoechst DNA stain). Cells in the pA!uA group 15 
exhibited greater mtROS staining (red) compared to pUC19 
control, an effect that is reduced in pA!uA+d4T treated cells. 
FIG.16 provides a graph showing that d4T does not inhibit 
ATP release induced by Alu RNA. Moreover, primary human 
RPE cells treated with Alu RNA, for the times indicated in 20 
FIG. 16, release ATP. Cell culture supernatant was collected 
from mock or Alu RNA treated cells, with or without d4 T, and 
ATP was detected using an ATP-dependent luciferase assay. 
Notably, d4T did not affect ATP release. 
FIG. 17 shows that d4T reduces ATP-induced cell perme- 25 
ability to Yo-Pro! (P2X7 receptor assay). Indeed, d4T dose-
dependently reduced Yo-Pro entry induced by ATP, deter-
mined by an area-scan fluorescent measurement in a 96 well 
microplate reader. FIG. 17 provides the results of the fluores-
cence measurement in relative fluorescence units (RFU, 30 
y-axis). 
FIG. 18 illustrates, in graph format, that d4T reduces extra-
cellular potassium levels, which increase after Alu RNA 
transfection. Indeed, cell culture potassium levels increase in 
primary human RPE cells treated withA!u RNA for 6 hours, 35 
an effect that is reduced by d4 T co-administration. Potassium 
levels were determined in cell culture supernatants spectra-
photometrically using a potassium-dependent pyruvate 
kinase assay. 
FIG. 19 shows that d4T blocks bzATP-induced cell perme- 40 
ability to Yo-Pro! (P2X7 receptor assay). To prepare FIG. 19, 
d4 T blocked YO-PRO-I iodide entry in HEK293 cells stably 
expressing the human P2X7 receptor stimulated with the 
P2X7 -selective agonist bzATP. Cells were pre-incubated with 
d4T for 30 minutes prior to addition ofbzATPNO-PRO, and 45 
fluorescence (in relative fluorescence units) at 485/515 urn 
was measured at t=30 minutes. 
FIG. 20 provides a chemical structure of methoxy-d4T 
(me-d4T). More specifically, as shown in FIG. 20, a single 
substitution of the ribose 5' hydroxyl group of d4T with a 50 
methoxy group (circled) has been designed to prevent d4T 
phosphorylation 
FIG. 21 is a Western blot of Caspase-1 activation (p20 
subunit) in primary human RPE cells transfected with Alu 
RNA±me-d4 T. 55 
FIG. 29 provides the methoxy variant of a nucleoside ana-
log. The chemical structure of3TC (2'3' dideoxycytidine) is 
shown, wherein the methoxy variation (0-methyl group) of 
nucleoside analog is circled. 
FIG. 30 provides the methoxy variant of a nucleoside ana-
log. The chemical structure of AZT (3'-azido-2',3'-dideox-
ythymidine) is shown, wherein the methoxy variation (O-rne-
thy! group) of nucleoside analog is circled. 
FIG. 31 provides the methoxy variant of a nucleoside ana-
log. The chemical structure of ABC ( cyclopropylaminopuri-
nylcyclopentene) is shown, wherein the methoxy variation 
(0-methyl group) of nucleoside analog is circled. 
FIG. 32 shows a cell permeant variant of d4T (IC-d4T), 
where "n" group is equal to 11. Derivatives include cell per-
meant variants of 3TC, AZT, ABC, where the nucleobase 
group (circled) may be replaced, in various embodiments, by 
3TC, AZT, ABC, or methoxy-variants of d4T, 3TC, AZT, 
ABC (FIG. 29-31), or derivatives thereof. 
FIG. 33 provides the structure of an exemplary NRTI 
according to the present disclosure. 
FIG. 34 is a Western blot of Caspase-1 activation (p20 
subunit) and IRAK4 phosphorylation in primary human RPE 
cells transfected withA!u RNA±d4T. 
FIG. 35 is a Western blot ofCaspase-1 activation in human 
RPE cells transfected with Alu RNA±NRTis (3TC, AZT, 
ABC). 
FIG. 36 includes fundus photographs: top row; flat mounts 
stained for zonula occludens-1 (Z0-1; red), bottom row. bars, 
50 fllll· 
FIG. 37 provides fundus photographs: top row; flat mounts 
stained for zonula occludens-1 (Z0-1; red), bottom row. 
Scale bars, 50 flill. 
FIG. 38 illustrates that NRTis block LPS/ATP-induced 
inflammasome activation. Specifically, FIG. 38 shows a gel 
indicating that d4T blocked Caspase-1. 
FIG. 39 also illustrates that NRTis block LPS/ATP-in-
duced inflmasome activation, showing specifically a gel 
indicating that d4T blocked IL-l beta. 
FIG. 40 presents chromatograms showing that Raji TK+ 
cells, but not Raji TK- cells, phosphorylate AZT to AZT-
triphosphate (AZT-TP) as determined by liquid chromatog-
raphy-mass spectrometry (LC-MS). 
FIG. 41 shows that AZT blocks IL-l beta activation by 
LPS/ATP in both Raji TK- and TK+ cells, as determined by 
Western blot of celllysates. 
FIG. 22 shows cells, wherein unmodified d4T, but not 
me-d4 T, blocks replication of a GFP-expressing lentivirus in 
HeLa cells. 
FIG. 23 provides a graph illustrating that unmodified d4T, 
but not me-d4T, reduces mtDNA levels (normalized to chro-
mosomal DNA exon-intron junction sequence) in primary 
mouse RPE cells as determined by real-time quantitative 
PCR. n=4, *p<0.05 by Student's t-test. 
FIG. 42 is a bar graph illustrating that d4T does not block 
Alu-induced ATP release from primary human RPE cells 
60 (n=4). 
FIG. 24 provides flat mounts stained for zonula 
occludens-1 (Z0-1; red), bottom row. Degeneration outlined 
by blue arrowheads. Representative images ofn=4 (B, C, E) 
shown. Scale bars, (C): 200 flill; (E): 20 flill 
FIG. 43 provides a graph of P2X7-mediated YO-PR0-1 
dye uptake (fluorescence) induced by bzATP (100 f.LM) in 
HEK293 cells stably expressing the human P2X7 receptor 
was inhibited by d4T and A438079 (64 f.LM for both drugs). 
65 Fluorescence values are baseline subtracted from cells with-
out bzATP treatment. *bzATP vs. d4T; #bzATP vs.A438079, 
p<0.05 by Student-Newman Keuls post-hoc test (n=12). 
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FIG. 44 is a Western blot of Caspase-1 activation (p20 
subunit) and IRAK4 phosphorylation in primary mouse RPE 
cells transfected withAlu RNA±d4T. 
FIG. 45 is a Northern blot ofbiotin-UTP-labeledAlu RNA-
transfected primary human RPE cells. 
FIG. 46 provides LC-MS/MS spectra ofAZT-triphosphate 
(AZT-TP). 
8 
characteristic( s) or limitation(s) and vice versa, unless other-
wise specified or clearly implied to the contrary by the context 
in which the reference is made. 
All combinations of method or process steps as used herein 
can be performed in any order, unless otherwise specified or 
clearly implied to the contrary by the context in which the 
referenced combination is made. 
FIG. 47 provides LC-MS/MS spectra ofAZU-triphosphate 
(AZT-TP 
FIG. 48 shows the chromatographic separation ofRaji TK-
cells spiked with AZT-TP with MS spectra (inset) to confirm 
identity of designated peaks. 
While the following terms used herein are believed to be 
well understood by one of ordinary skill in the art, definitions 
10 are set forth to facilitate explanation of the presently-dis-
closed subject matter. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which the presently-
FIG. 49 shows the chromatographic separation ofRaji TK-
cells spiked withAZU-TP with MS spectra (inset) to confirm 
identity of designated peaks. 
FIG. 50 is a standard curve of AZT-TP standards (black 
circle). As shown, Raji TK+ samples treated withAZT pro-
duced AZT-TP (white triangles), whereas AZT-TP was not 
detectable in Raji TK- cells treated withAZT. 
15 disclosed subject matter belongs. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently-
disclosed subject matter, representative methods, devices, 
and materials are now described. 
FIG. 51 is a Western blot of Caspase-1 activation (p20 20 
subunit) in primary human RPE cells transfected with Alu 
RNA, with short peptide (Panx1 10), which blocks P2X7 pore 
function but not cation flux (vs. scrambled peptide: Scr 
Panx1 10). 
FIG. 52 is a Western blot of Caspase-1 activation (p20 25 
subunit) in primary human RPE cells transfected with Alu 
RNA, with calmidazolium (FIG. 32 provides the chemical 
structure ofiC- and EC-d4T used), which blocks P2X7 cation 
flux but not pore function. 
FIG. 53 is a Western blot of Caspase-1 activation (p20 30 
subunit) in primary human RPE cells transfected with Alu 
RNA, with cell permeable (IC), cell-impermeable (EC), or 
unmodified (no tag) d4T. 
FIG. 54 shows that d4 T prevents pAlu-induced mitochon-
drial ROS generation in primary human RPE cells. In FIG. 54, 35 
mitochondrial reactive oxygen species (ROS) were visual-
ized with MitoSox (Red) and cell nuclei with Hoechst (Blue). 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a fluorophore" includes a plurality of such images, 
and so forth. 
Unless otherwise indicated, all numbers expressing quan-
tities, properties, and so forth used in the specification and 
claims are to be understood as being modified in all instances 
by the term "about". Accordingly, unless indicated to the 
contrary, the numerical parameters set forth in this specifica-
tion and claims are approximations that can vary depending 
upon the desired properties sought to be obtained by the 
presently-disclosed subject matter. 
As used herein, the term "about," when referring to a value 
or to an amount of mass, weight, time, volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments ±50%, in some embodiments ±40%, in some 
embodiments ±30%, in some embodiments ±20%, in some 
embodiments ±10%, in some embodiments ±5%, in some 
embodiments ±1%, in some embodiments ±0.5%, and in DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 40 some embodiments ±0.1% from the specified amount, as such 
variations are appropriate to perform the disclosed method. 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. Modi-
fications to embodiments described in this document, and 
other embodiments, will be evident to those of ordinary skill 45 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the specific details of the described exemplary 
embodiments, is provided primarily for clearness of under-
standing and no unnecessary limitations are to be understood 50 
therefrom. In case of conflict, the specification of this docu-
ment, including definitions, will control. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "1 0" is disclosed, then "about 1 0" is 
also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, iflO and 
15 are disclosed, then 11, 12, 13, and 14 are also disclosed. 
The term "physiologically functional derivative" means 
any pharmaceutically acceptable derivative of a compound of 
the present disclosure. For example, an amide or ester of a 
compound of formula (I) or of a compound of formula (II), 
which upon administration to a subject, particularly a mam-
mal, is capable of providing, either directly or indirectly, a 
compound of the present disclosure of an active metabolite 
thereof. 
The terms "treatment" or "treating" refer to the medical 
management of a subject with the intent to cure, ameliorate, 
stabilize, or prevent a condition or disorder (e.g., retinal deg-
radation). This term includes active treatment, that is, treat-
ment directed specifically toward the improvement of a con-
dition, and also includes causal treatment, that is, treatment 
The presently-disclosed subject matter is illustrated by 
specific but non-limiting examples throughout this descrip-
tion. The examples may include compilations of data that are 55 
representative of data gathered at various times during the 
course of development and experimentation related to the 
present invention(s). Each example is provided by way of 
explanation of the present disclosure and is not a limitation 
thereon. In fact, it will be apparent to those skilled in the art 60 
that various modifications and variations can be made to the 
teachings of the present disclosure without departing from the 
scope of the disclosure. For instance, features illustrated or 
described as part of one embodiment can be used with another 
embodiment to yield a still further embodiment. 65 directed toward removal of the cause of the associated con-
All references to singular characteristics or limitations of 
the present disclosure shall include the corresponding plural 
dition. In addition, this term includes palliative treatment, that 
is, treatment designed for the relief of symptoms rather than 
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the curing of the condition; preventative treatment, that is, 
treatment directed to minimizing or partially or completely 
inhibiting the development of symptoms or disorders of the 
associated condition; and supportive treatment, that is, treat-
ment employed to supplement another specific therapy 
directed toward the improvement of the associated disease, 
pathological condition, or disorder. 
10 
goat, cow, cat, guinea pig, rodent, and non-mmals). The 
term "subject" does not denote a particular age or sex. Thus, 
adult and newborn subjects, as well as fetuses, whether male 
or female, are intended to be covered. The term "subject" 
includes human and veterinary subjects. 
As will be recognized by one of ordinary skill in the art, the 
terms "suppression," "suppressing," "suppressor," "inhibi-
tion," "inhibiting" or "inhibitor" do not refer to a complete 
elimination of angiogenesis in all cases. Rather, the skilled 
10 artisan will understand that the term "suppressing" or "inhib-
iting" refers to a reduction or decrease in angiogenesis. Such 
reduction or decrease can be determined relative to a control. 
In some embodiments, the reduction or decrease relative to a 
With regard to administering the compound, the term 
"administering" refers to any method of providing a compo-
sition and/or pharmaceutical composition thereof to a sub-
ject. Such methods are well known to those skilled in the art 
and include, but are not limited to, oral administration, trans-
dermal administration, administration by inhalation, nasal 
administration, topical administration, intravaginal adminis-
tration, ophthalmic administration, intraaural administration, 15 
intracerebral administration, rectal administration, and 
parenteral administration, including injectable such as intra-
venous administration, intra-arterial administration, intra-
muscular administration, subcutaneous administration, intra-
vitreous administration, including via intravitreous sustained 20 
drug delivery device, intracameral (into anterior chamber) 
administration, suprachoroidal injection, subretinal adminis-
tration, Subconjunctival injection, sub-Tenon's administra-
tion, peribulbar administration, Transscleral drug delivery, 
administration via topical eye drops, and the like. Adminis- 25 
tration can be continuous or intermittent. In various aspects, a 
preparation can be administered therapeutically; that is, 
administered to treat an existing disease or condition (e.g., 
exposure to OP compounds). In further various aspects, a 
preparation can be administered prophylactically; that is, 30 
administered for prevention of a disease or condition. 
The term "effective amount" refers to an amount that is 
sufficient to achieve the desired result or to have an effect on 
controlcanbeabouta 1,2,3,4, 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 
15, 16,17, 18, 19,20,21,22,23,24,25,26,27,28,29,30,31, 
32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48, 
49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65, 
66,67,68,69, 70, 71, 72,73, 74, 75, 76, 77,78, 79,80,81,82, 
83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99, 
or 100% decrease. 
In some exemplary embodiments, the presently-disclosed 
subject matter includes methods for treating retinal damage 
and/or retinal degeneration. Indeed, some methods of the 
present disclosure comprise administering to a subject in 
need thereof an effective amount of a composition for treating 
retinal damage and/or degradation. 
In some embodiments the composition comprises a 
nucleoside and/or a nucleoside reverse transcriptase inhibitor 
(NRTI). Further, in some embodiments, the composition is a 
pharmaceutical composition comprising a nucleoside and/or 
a NRTI compound as well as a pharmaceutically acceptable 
earner. 
As discussed herein, in some exemplary methods of the 
present disclosure, the administered composition is a compo-
35 sition comprising a nucleoside and/or NRTI. Thus, exemplary 
compositions are comprised of compounds including, but not 
limited to, stavudine (d4T), lamivudine (3TC), cordycepin, 
azidothymidine (AZT), abacavir (ABC), chemical deriva-
tives thereof (e.g., methoxy-derivatives to abrogate phospho-
an undesired condition. For example, a "therapeutically 
effective amount" refers to an amount that is sufficient to 
achieve the desired therapeutic result or to have an effect on 
undesired symptoms, but is generally insufficient to cause 
adverse side effects. The specific therapeutically effective 
dose level for any particular patient will depend upon a vari-
ety of factors including the disorder being treated and the 
severity of the disorder; the specific composition employed; 
the age, body weight, general health, sex and diet of the 
patient; the time of administration; the route of administra-
tion; the rate of excretion of the specific compound employed; 
the duration of the treatment; drugs used in combination or 
coincidental with the specific compound employed and like 
factors well known in the medical arts. For example, it is well 
within the skill of the art to start doses of a compound at levels 
lower than those required to achieve the desired therapeutic 
effect and to gradually increase the dosage until the desired 50 
effect is achieved. If desired, the effective daily dose can be 
divided into multiple doses for purposes of administration. 
Consequently, single dose compositions can contain such 
amounts or submultiples thereof to make up the daily dose. 
The dosage can be adjusted by the individual physician in the 55 
event of any contraindications. Dosage can vary, and can be 
administered in one or more dose administrations daily, for 
one or several days. Guidance can be found in the literature 
for appropriate dosages for given classes of pharmaceutical 
products. In further various aspects, a preparation can be 60 
administered in a "prophylactically effective amount"; that is, 
an amount effective for prevention of a disease or condition. 
40 rylation), and the like. Other possible compounds include, for 
example, those described in U.S. Pat. No. 6,514,979 to 
Heredia et a!. Those of ordinary skill in the art will also 
recognize further nucleosides and/or NRTis, as described 
herein, that can be used in the compositions and methods of 
45 this disclosure. 
In some embodiments a method of the present disclosure 
comprises inhibiting activation of one or more physiological 
processes by Alu RNA. As disclosed herein, Alu RNA (in-
cluding Alu repeat RNA in human cells and B1 and B2, 
Alu-like element repeat RNAs) increases are associated with 
cells that are associated with certain conditions of interest. 
For example, an Alu RNA increase is associated with the 
retinal pigment epithelium (RPE) cells of eyes with geo-
graphic atrophy. This increase of Alu RNA induces the death 
ofRPE cells. Methods and compositions disclosed herein can 
treat RPE degradation, thereby treating conditions associated 
with such cell death. 
The terms "subject" or "subject in need thereof' refer to a 
target of administration, which optionally displays symptoms 
related to a particular disease, condition, disorder, or the like. 65 
The subject(s) of the herein disclosed methods can be human 
In some embodiments, a method of the present disclosure 
comprises inhibiting the activation of at least one inflamma-
some. In certain embodiments, the at least one inflmasome 
is selected from an NLRP3 inflammasome, a 1 L-1 beta 
inflammasome, and a combination thereof. In some embodi-
ments, the inhibiting one or more inflammasomes of a cell 
includes administering an inhibitor (composition) to the cell 
and/or to a subject, wherein the cell is the cell of a subject. For 
compositions comprising an inhibitor, an inhibitor as 
described herein can be, for example, a polypeptide inhibitor or non-human (e.g., primate, horse, pig, rabbit, dog, sheep, 
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(including an oligonucleotide inhibitor), a small molecule 
inhibitor, and/or an siRNA inhibitor. 
Moreover, some exemplary methods of administering the 
present composition(s) can inhibit inflammation by LPS/ 
ATP, inflammasome activation by LPS/ATP, inflammasome 
activation by Alu RNA, and/or nigericin-induced inflamma-
some activation. Exemplary methods can also treat retinal 
degradation and/or other retinal damage by reducing mito-
chondrial reactive oxygen species, particularly as caused by 
Alu RNA expression, by blocking entry via the P2X7 recep-
tor, and/or by reducing ATP-induced cell permeability. 
In some embodiments, a method of the present disclosure 
comprises treating retinal damage by inhibiting a particular 
action in a cell. In some embodiments, the cell is selected 
from an RPE cell, a retinal photoreceptor cell, or a choroidal 
cell. In some embodiments, the cell is an RPE cell. In some 
embodiments, the cell is the cell of a subject. In some embodi-
ments, the cell is a cell of a subject having, suspected of 
having, or at risk of having a condition of interest. In some 
embodiments, the cell is a cell of a subject having, suspected 
of having, or at risk of having age-related macular degenera-
tion. In some embodiments, the cell is a cell of a subject 
having, suspected of having, or at risk of having geographic 
atrophy. In some embodiments, the cell is a cell of a subject 
having, suspected of having, or at risk of having geographic 
atrophy and the cell is an RPE cell. In some embodiments, a 
subject having age-related macular degeneration can be 
treated using methods and compositions as disclosed herein. 
Thus, as used herein with reference to a polypeptide being 
inhibited, "of a cell" refers to a polypeptide that is inside the 
cell (inside the cell membrane), on the cell (in the cell mem-
brane, presented on the cell membrane, otherwise on the cell), 
or outside of a cell, but insofar as the polypeptide is outside of 
the cell, it is in the extracellular milieu such that one of 
ordinary skill in the art would recognize the polypeptide as 
being associated with the cell. For example, VDACl, 
VDAC2, caspase-8, NFKB, or a polypeptide of an inflamma-
some (e.g., NLRP3, PYCARD, caspase-1) could be in the 
cell. For another example, NLRP3 could be in the cell or on 
the cell. 
As described herein, the presently-disclosed subject matter 
further includes pharmaceutical compositions comprising the 
compounds described herein together with a pharmaceuti-
cally acceptable carrier. 
The term "pharmaceutically acceptable carrier" refers to 
sterile aqueous or nonaqueous solutions, dispersions, suspen-
sions or emulsions, as well as sterile powders for reconstitu-
tion into sterile injectable solutions or dispersions just prior to 
use. Proper fluidity can be maintained, for example, by the 
use of coating materials such as lecithin, by the maintenance 
of the required particle size in the case of dispersions and by 
the use of surfactants. These compositions can also contain 
adjuvants such as preservatives, wetting agents, emulsifying 
agents and dispersing agents. Prevention of the action of 
microorganisms can be ensured by the inclusion of various 
antibacterial and antifungal agents such as para ben, chlorobu-
tanol, phenol, sorbic acid and the like. It can also be desirable 
to include isotonic agents such as sugars, sodium chloride and 
the like. Prolonged absorption of the injectable pharmaceuti-
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are also prepared by entrapping the drug in liposomes or 
microemulsions which are compatible with body tissues. The 
injectable formulations can be sterilized, for example, by 
filtration through a bacterial-retaining filter or by incorporat-
ing sterilizing agents in the form of sterile solid compositions 
which can be dissolved or dispersed in sterile water or other 
sterile injectable media just prior to use. Suitable inert carriers 
can include sugars such as lactose. 
Suitable formulations include aqueous and non-aqueous 
10 sterile injection solutions that can contain antioxidants, buff-
ers, bacteriostats, bactericidal antibiotics and solutes that ren-
der the formulation isotonic with the bodily fluids of the 
intended recipient; and aqueous and non-aqueous sterile sus-
pensions, which can include suspending agents and thicken-
15 ing agents. 
The compositions can take such forms as suspensions, 
solutions or emulsions in oily or aqueous vehicles, and can 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Alternatively, the active ingredient 
20 can be in powder form for constitution with a suitable vehicle, 
e.g., sterile pyrogen-free water, before use. 
The formulations can be presented in unit-dose or multi-
dose containers, for example sealed ampoules and vials, and 
can be stored in a frozen or freeze-dried (lyophilized) condi-
25 tion requiring only the addition of sterile liquid carrier imme-
diately prior to use. 
For oral administration, the compositions can take the form 
of, for example, tablets or capsules prepared by a conven-
tional technique with pharmaceutically acceptable excipients 
30 such as binding agents (e.g., pregelatinized maize starch, 
polyvinylpyrrolidone or hydroxypropyl methylcellulose ); 
fillers (e.g., lactose, microcrystalline cellulose or calcium 
hydrogen phosphate); lubricants (e.g., magnesium stearate, 
talc or silica); disintegrants (e.g., potato starch or sodium 
35 starch glycollate ); or wetting agents (e.g., sodium Iaury! sul-
phate). The tablets can be coated by methods known in the art. 
Liquid preparations for oral administration can take the 
form of, for example, solutions, syrups or suspensions, or 
they can be presented as a dry product for constitution with 
40 water or other suitable vehicle before use. Such liquid prepa-
rations can be prepared by conventional techniques with 
pharmaceutically acceptable additives such as suspending 
agents (e.g., sorbitol syrup, cellulose derivatives or hydroge-
nated edible fats); emulsifYing agents (e.g. lecithin or acacia); 
45 non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alco-
hol or fractionated vegetable oils); and preservatives (e.g., 
methyl or propyl-p-hydroxybenzoates or sorbic acid). The 
preparations can also contain buffer salts, flavoring, coloring 
and sweetening agents as appropriate. Preparations for oral 
50 administration can be suitably formulated to give controlled 
release of the active compound. For buccal administration the 
compositions can take the form of tablets or lozenges formu-
lated in conventional manner. 
The compositions can be formulated as eye drops. For 
55 example, the pharmaceutically acceptable carrier may com-
prise saline solution or other substances used to formulate eye 
drop, optionally with other agents. Thus, eye drop formula-
tions permit for topical administration directly to the eye of a 
subject. 
cal form can be brought about by the inclusion of agents, such 60 
as aluminum mono stearate and gelatin, which delay absorp-
tion. Injectable depot forms are made by forming microen-
capsule matrices of the drug in biodegradable polymers such 
The compositions can also be formulated as a preparation 
for implantation or injection. Thus, for example, the com-
pounds can be formulated with suitable polymeric or hydro-
phobic materials (e.g., as an emulsion in an acceptable oil) or 
ion exchange resins, or as sparingly soluble derivatives (e.g., as polylactide-polyglycolide, poly(orthoesters) and poly( an-
hydrides). Depending upon the ratio of drug to polymer and 
the nature of the particular polymer employed, the rate of 
drug release can be controlled. Depot injectable formulations 
65 as a sparingly soluble salt). The compounds can also be for-
mulated in rectal compositions, creams or lotions, or trans-
dermal patches. 
US 9,326,983 B2 
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The presently-disclosed subject matter further includes a 
kit that can include a compound or pharmaceutical composi-
tion as described herein, packaged together with a device 
useful for administration of the compound or composition. As 
will be recognized by those or ordinary skill in the art, the 
appropriate administration-aiding device will depend on the 
formulation of the compound or composition that is selected 
and/or the desired administration site. For example, if the 
formulation of the compound or composition is appropriate 
for injection in a subject, the device could be a syringe. For 10 
another example, if the desired administration site is cell 
culture media, the device could be a sterile pipette. 
Moreover, NRTis of the present disclosure are a diverse, 
widely used, inexpensive class of small molecules, with 15 
extensive pharmacokinetic and safety data collected over the 
past several decades of human use; NRTis are therefore ripe 
for drug repurposing. As such, the present disclosure provides 
a novel and broadly applicable basis for use of one or more 
NRTis by addressing major unmet medical needs. 20 
As briefly described above, age-related macular degenera-
tion is a disease that affects tens of millions of people world-
wide, and there is no effective treatment for AMD (Ambati 
and Fowler, 2012). Similarly, graft-versus host disease is the 25 
major obstacle preventing successful tissue transplant (Fer-
rara et a!., 2009); and sterile liver inflammation is a major 
contributor to drug-induced liver injury and steatohepatitis, a 
major determinant of fibrosis and carcinogenesis (Kubes and 30 
Mehal, 2012). Thus, some methods and/or compounds of the 
present disclosure are intended to treat age-related macular 
degeneration, graft-versus host disease, and/or sterile liver 
inflammation by administering, in some embodiments, a 
compound comprising at least one NRTI, as provided in the 35 
present disclosure. 
Since inflmasome inhibition by NRTis can be achieved 
without phosphorylation of a particular NRTI, the use of 
me-d4T or other phosphorylation-incompetent nucleoside 40 
analogs, as provided herein, should avoid therapeutic-limit-
ing toxicities associated with NRTI-triphosphate-mediated 
polymerase inhibition (Lewis et a!., 2003). Accordingly, in 
some embodiments, the present disclosure is directed to 
methods for treating retinal disease by administering me-d4 T 45 
or another phosphorylation-incompetent nucleoside analog 
to a subject in need thereof. 
Further, in certain embodiments, the present disclosure 
provides methods for treating retinal damage, comprising: 
administering an effective amount of a composition to a sub- 50 
ject in need thereof, wherein the composition comprises an 
NRTI. In some embodiments, the NRTI is selected from the 
group consisting of stavudine (d4T), lamivudine (3TC), 
cordycepin, azidothymidire (AZT), abacavir (ABC), or 
derivatives or combinations thereof. 55 HO 
In some embodiments, the presently disclosed subject mat-
ter provides methods for protecting an RPE cell, a retinal 
photoreceptor cell, a choroidal cell, or a combination thereof 
comprising at least the step of administering a composition 60 
that comprises at least one nucleoside analog or NRTI, 
according to the present disclosure, to a subject in need 
thereof. 
Moreover, in some embodiments, the present disclosure is 
directed to the synthesis and/or use of one or more com- 65 
pounds of Formula I, Formula II, Formula III, Formula IV, 
and/or Formula IV: 
0 
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(I) 
(II) 
(III) 
(IV) 
and/or 
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drug-induced lung inflammation, contact dermatitis, leprosy, 
Burkholderia cenocepacia infection, respiratory syncitial 
virus infection, psoriasis, scleroderma, reactive arthritis, cys-
tic fibrosis, syphilis, Sjogren's syndrome, inflammatory joint 
disease, non-alcoholic fatty liver disease, cardiac surgery 
(peri-/post-operative inflammation), acute and chronic organ 
transplant rejection, acute and chronic bone marrow trans-
plant rejection, tumor angiogenesis, and/or any combination 
thereof. 
Moreover, in some embodiments, the present disclosure 
provides that non-canonical NRTI function, independent of 
chain termination, prevents P2X7-dependent blindness, 
graft-versus-host disease and/or sterile inflammation. 
Accordingly, the present disclosure is directed, in certain 
and/or to any salt, particularly any pharmaceutically accept-
able salt, any solvate, and/or any physiological derivative 
thereof. In some embodiments, "n" of Formula IV is any 
integer, and in a particular embodiment, n is 11. 
15 embodiments, to methods of preventing P2X7-dependent 
blindness, graft-versus-host disease and/or inflammation in a 
subject by administering an effective amount of at least one 
NRTI, as described herein, to subject in need thereof. 
Further, in certain embodiments, the methods and compo-
Further, the present disclosure provides uses of a com-
pound of any of Formulas (I), (II), (III), (IV) and/or (IV), or 
any combination thereof, in the preparation or manufacture of 
a pharmaceutical composition, such as a drug and/or medi-
cine, especially a composition for the treatment of retinal 
damage and/or retinal degeneration in a mammal. In some 
embodiments, the present disclosure provides a pharmaceu-
tical composition comprising a compound of any ofFormulas 
20 sitions of the present disclosure inhibit (i) inflammasome 
activation by Alu RNA associated with a cell; (ii) inflamma-
tion by LPS/ ATP, (iii) inflammasome activation by LPS/ ATP, 
(iv) nigericin-induced inflammasome activation, and/or com-
binations thereof. And in some embodiments, the inflamma-
25 some is selected from the group consisting of a NLRP3 
inflammasome and/or a 1L-1 beta inflammasome. Addition-
(I), (II), (III), (IV) and/or (IV), any salt, particularly any 
pharmaceutically acceptable salt, any solvate, and/or any 30 
physiological derivative thereof, together with a pharmaceu-
tically acceptable carrier. 
In certain embodiments, the methods and compositions of 
the present disclosure inhibit graft-versus-host disease, 
chronic pain, proliferative vitreoretinopathy, glaucoma, rheu- 35 
matoid arthritis, multiple sclerosis, bipolar disorder, major 
depressive disorder, renal fibrosis, nephritis, pulmonary 
fibrosis, Huntington's disease, osteoporosis, chronic lympho-
cytic leukemia, anxiety disorders, pulmonary tuberculosis, 
osteoporosis in post-menopausal women and fracture 40 
patients, systemic lupus erythematosus, chronic inflamma-
tory and neuropathic pain, autosomal dominant polycystic 
kidney disease, spinal cord injury, Alzheimer's disease, neu-
ropathic pain, hypertension, varicose veins, type I diabetes, 
type II diabetes, gout, autoimmune hepatitis, graft vascular 45 
injury, atherosclerosis, thrombosis, metabolic syndrome, 
salivary gland inflammation, traumatic brain injury, ischemic 
heart disease, ischemic stroke, Parkinson's disease, mela-
noma, neuroblastoma, prostate, breast, skin, and thyroid can-
cers, tubular early gastric cancer, neuroendocrine cancer, 50 
mucoid colon cancer, colon cancer; high-grade urothelial 
carcinoma, kidney clear cell carcinoma, undifferentiated 
ovary carcinoma, papillary intracystic breast carcinoma, 
gram negative sepsis, infectious Pseudomonas aeruginosa, 
Vibrio cholera, Legionella spp., Francis ella spp., and Leish- 55 
mania spp. Chlamydia spp., cryopyrinopathies; keratitis, 
acne vulgaris, Crohn's disease, ulcerative colitis, irritable 
bowel syndrome, insulin resistance, obesity, hemolytic-ure-
mic syndrome, polyoma virus infection, immune complex 
renal disease, acute tubular injury, lupus nephritis, familial 60 
cold autoinflammatory syndrome, Muckle-Wells syndrome 
and neonatal onset multisystem inflammatory disease, 
chronic infantile neurologic cutaneous and articular autoin-
flammatory diseases, renal ischemia-perfusion injury, glom-
erulonephritis, cryoglobulinemia, systemic vasculitides, IgA 65 
nephropathy, malaria, helminth parasites, septic shock, aller-
gic asthma, hay fever, chronic obstructive pulmonary disease, 
ally, some embodiments of the methods of the present disclo-
sure may include, for example, the steps of (i) blocking entry 
via a P2X7 receptor associated with a cell; (ii) reducing 
mitochondrial reactive oxygen species caused by Alu RNA 
expression; and/or (iii) reducingATP-induced cell permeabil-
ity of a cell. And a cell contemplated in the present disclosure 
may include, for example, an RPE cell, a retinal photorecep-
tor cell, a choroidal cell, or any combination thereof. 
Further, NRTis are mainstay therapeutics for HIV, and they 
block retrovirus replication. Alu RNA, an endogenous retro-
element that also requires reverse transcriptase (RT) for its 
life cycle, activates the NLRP3 inflammasome to cause cell 
death of the retinal pigment epithelium in geographic atrophy, 
which is the untreatable form of age-related macular degen-
eration that blinds millions of individuals. Moreover, the 
inventors of the present disclosure have found that NRTis, as 
a class, are novel inhibitors of the NLRP3 inflammasome. 
And, surprisingly, this effect is independent of reverse tran-
scriptase inhibition. 
Thus, the inventors of the present disclosure have found 
that the NRTis d4T, AZT, ABC, and 3TC block Caspase 1 
activation by Alu RNA, as does 5'-methoxy-d4T, which does 
not inhibit reverse transcriptase. Further, the present inven-
tors have found that AZT is not phosphorylated in thymidine 
kinase-deficient cells but still blocks LPS/ ATP-induced inter-
leukin-1 beta secretion; that NRTis block P2X7 -dependent 
YOPR0-1 dye uptake in mouse models of geographic atro-
phy, graft-versus-host disease, and sterile liver inflammation; 
and that NRTis are novel inhibitors of the NLRP3 inflamma-
some independent of canonical reverse transcriptase inhibi-
tion. Accordingly, NRTis are ripe for drug repurposing in a 
variety of P2X7 -driven diseases. 
NRTis were first discovered to be anti-viral compounds in 
1974 (Ostertag et a!., 1974), and are widely used to treat 
human immunodeficiency virus (HIV). The canonical 
mechanism of action of NRTis is via chain termination of 
DNA synthesis from a viral RNA template, thereby interfer-
ing with the viral life cycle of reverse transcriptase-dependent 
v1ruses. 
Age-related macular degeneration (AMD) is a leading 
cause of blindness in the elderly worldwide (Ambati et a!., 
US 9,326,983 B2 
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2003; Ambati and Fowler, 2012). In the more prevalent and 
untreatable dry form of AMD, overabundance of non-coding 
Alu RNAs causes blindness by inducing cell death of the 
retinal pigment epithelium (Dridi eta!., 2012; Kaneko eta!., 
2011; Tarallo et a!., 2012). Alu sequences are non-coding 5 
retrotransposons that, like HIV, rely on reverse transcriptase 
for their life cycle (Batzer and Deininger, 2002; Dewannieux 
eta!., 2003). 
18 
Caspase-1 directly processes interleukin 1 beta (IL-l beta) 
upon LPS/ATP stimulation; d4T also blocks secretion of 
mature IL-l beta in these cells (FIG. 39). To determine 
whether LPS/ATP-induced inflammasome activation can be 
inhibited without RT inhibition, the present inventors utilized 
thymidine kinase-deficient (Raji/TK-) and -expressing (Raji/ 
TK+) cells (Balzarini eta!., 1989). After addition of AZT, 
TK+, but not TK- cells, the present inventors producedAZT-
triphosphate (AZT-TP), the AZT metabolite required for RT 
10 inhibition (FIG. 40; FIG. 46, FIG. 47, FIG. 48, FIG. 49, FIG. 
50). Even though AZT was not phosphorylated in TK- cells, 
AZT still inhibited LPS/ ATP-induced interleukin-1 beta 
maturation (FIG. 41), indicating that AZT did not inhibit 
Alu RNA mediates RPE cell death via activation of 
Caspase 1 and the NLRP3 inflammasome (Tarallo et a!., 
2012). The present disclosure provides that a reverse tran-
scriptase inhibitor, such as stavudine (d4T; 2'3' dideoxythy-
midine; Zerit, Bristol-Myers Squibb), which is FDA-ap-
proved for the treatment ofHIV, prevents Caspase 1 cleavage 15 
to its active 20 kDa form (Hentze eta!., 2003; Yamin eta!., 
1996) inprimaryhuman(FIG. 34) andmouseRPE cells (FIG. 
44) without reducing Alu RNA levels (FIG. 45). Further, the 
present disclosure shows that d4T also blocks phosphoryla-
tion ofiRAK4, a kinase downstream of the MyD88 adaptor 20 
that mediates Alu-induced RPE cell death (Tarallo et a!., 
2012), in human and mouse RPE cells (FIG. 34 and FIG. 44). 
The inventors of the present disclosure have also found that 
other NRTis, including the anti-HIV drugs azidothymidine 
(AZT; 3'-azido-2',3'-dideoxythymidine; Retrovir, ViiV 25 
Healthcare), lamivudine (3TC; 2'3' dideoxycytidine; Zeffix, 
GlaxoSmithKline) and abacavir (ABC; a di -deoxyguanosine 
analog; Ziagen, ViiV Healthcare ), also block Caspase-1 
cleavage induced by Alu RNA (FIG. 35). 
Additionally, the present disclosure provides that d4T and 30 
AZT prevent RPE degeneration in the Alu RNA-induced 
mouse model of dry AMD. (Kaneko eta!., 2011; Tarallo eta!., 
2012) Moreover, it has been found that mice receiving daily 
oral administration of d4T blocked RPE degeneration after 
sub-retinal injection of a plasmid expressing Alu RNA (FIG. 35 
36), as did intraperitoneal administration of AZT (FIG. 37). 
In order to test whether reverse transcriptase inhibition was 
required for inflammasome blockade by d4T, a 5' 0-methyl-
modified version of d4T (5'-0CH3-d4T; me-d4T) was syn-
thesized (FIG. 20; FIG. 25, FIG. 36, FIG. 27, FIG. 28). 40 
Accordingly, in some embodiments, the present disclosure is 
directed to methods for synthesizing a 5' 0-methyl-modified 
version of d4T as provided herein. 
Only the triphosphate version of nucleoside analogs inhibit 
reverse transcriptase; the methyl modification at the 5' posi- 45 
tion prevents phosphorylation and thus formation of nucleo-
side triphosphate (Nykanen eta!., 2001). Accordingly, like 
d4 T, me-d4 T also blocks Caspase-1 activation in human RPE 
cells (FIG. 21). 
interleukin -1 beta maturation via reverse transcriptase inhi-
bition. 
Alu RNA (Kerur et a!., 2013) and LPS/ATP (Qu et a!., 
2011) activate the inflammasome via the ATP receptor P2X7. 
The present inventors therefore hypothesized that d4 T blocks 
P2X7 or some P2X7-dependent pathway. First, testing was 
conducted to determine whether d4T acts upstream ofP2X7 
by modulating ATP levels; however, d4T does not block 
release of ATP to cell culture media induced by Alu RNA 
(FIG. 42). 
Next, testing was conducted to determine whether d4T 
directly antagonizes P2X7 function: uponATP binding, cell-
surface P2X7 forms non-selective cation channels that medi-
ate inflammasome activation (Kahlenberg and Dub yak, 2004; 
Petrilli et a!., 2007). However, d4T did not significantly 
modulate P2X7 cation channel function as monitored by 
patch clamp analysis ofHEK293 stable cell lines expressing 
either the human or rat P2X7 receptor (Humphreys et a!., 
2000). 
Finally, P2X7 activation is associated with the formation of 
a large pore that is permeable to molecules of up to -1000 Da 
(Adinolfi eta!., 2005; Cheewatrakoolpong eta!., 2005; Sur-
prenant eta!., 1996). It was found that d4T, and alsoAZT and 
3 TC, inhibited P2X7 -dependent uptake of the fluorescent dye 
YO-PRO! (M.W. Da) in human P2X7-overexpressing 
HEK293 stable cell line (FIG. 43) after addition of the selec-
tive P2X7 agonist bzATP. 
Consistent with the idea that NRTis block Alu-induced 
P2X7-mediated inflammasome activation via a mechanism 
involving dye uptake, Alu RNA-induced Caspase-1 activa-
tion was inhibited by a small peptide that blocks P2X7 -me-
diated dye uptake and LPS/ ATP-induced inflammasome acti-
vation, but not cation flux (Pelegrin and Surprenant, 2006) 
(FIG. 51). On the other hand, Alu-induced Caspase-1 activa-
tion was not inhibited by calmidazolium, which selectively 
blocks P2X7-mediated cation flux but not dye uptake (FIG. 
52). 
Furthermore, the intracellular C-terminus ofP2X7 governs 
P2X7 -associated dye uptake, and a version of d4T that is not 
cell permeable (Agarwal et a!., 2011) does not block 
caspase-1 activation by Alu RNA (FIG. 53, FIG. 32). Consis-
tent with antagonism at or downstream ofP2X7, but upstream 
of mitochondrial dysfunction, d4T blocks mitochondrial 
ROS (mtROS) production, which are produced upon LPS/ 
ATP stimulation (Adinolfi et a!., 2005; Cruz et a!., 2007; 
Garcia-Marcos eta!., 2005; Nakahira eta!., 2011) and Alu 
The present inventors have confirmed that me-d4 T does not 50 
inhibit reverse transcriptase: and, in contrast to uumodified 
d4T, me-d4T does not block lentivirus replication (FIG. 22). 
Also, the triphosphate metabolite of di-deoxy nucleoside ana-
logs caused depletion of mitochondrial DNA; and consistent 
with the idea that me-d4T is not phosphorylated, it has been 55 
found that d4T, but not me-d4T reduces mtDNA levels. (FIG. 
23). Me-d4T also prevents Alu-induced RPE degeneration in 
mice (FIG. 24). These data indicate that d4T can block 
Caspase-1 activation and RPE degeneration independent of 
reverse transcriptase inhibition. 
Further, the present inventors also tested whether NRTis 
blocked inflammasome activation by LPS/ATP, which is not 
known to signal via reverse transcriptase (Mariathasan et a!., 
2004; Mariathasan eta!., 2006; Martinon eta!., 2002). It was 
found that d4 T inhibited LPS/ ATP-induced Caspase-1 matu- 65 
ration in primary mouse bone marrow-derived macrophages 
(FIG. 38) as detected by Western blot. 
60 overexpression (Tarallo eta!., 2012) was measured by Mito-
SOx assay (FIG. 54). Finally, d4T does not prevent P2X7-
independent interleukin 1-beta secretion in PMA-primed 
THP-1 cells treated with crystalline monosodium urate (FIG. 
11) (Martinon eta!., 2006; Riteau eta!., 2012). 
To explore the potential therapeutic relevance of NRTis 
beyond the Alu-induced model of geographic atrophy (GA), 
it was hypothesized that ifNRTis function as generic inflam-
US 9,326,983 B2 
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Moreover, in some embodiments, d4 T does not reduce Alu 
RNA levels. For example, primary human RPE cells may be 
transfected withAlu RNA, with or without d4 T. (FIG. 4) And, 
as presented in FIG. 4, co-administration of d4T does not 
change Alu RNA levels at 1, 4, or 24 hours after transfection 
in the nuclear fraction, as detected by Northern blotting using 
anAlu-specific probe. U6 (bottom row) is shown as loading 
control for nuclear fraction in FIG. 4. 
The present disclosure further provides that, in some 
masome inhibitors, then they might be broadly useful in other 
animal models of disease that are also driven by P2X7. In the 
NLRP3 inflammasome- and P2X7-driven graft-versus-host 
disease model (Jankovic eta!., 2013; Wilhelm eta!., 2010), 
treatment of mice receiving allogeneic bone marrow and T 5 
cells with d4 T showed improved survival compared to saline 
treated controls (30-70% vs. 0%). Furthermore, in the 
NLRP3- and P2X7 -driven model of sterile inflammation 
(McDonald eta!., 201 0), d4 T reduced neutrophil migration to 
the focus of liver injury. 
Interestingly, it has been shown that P2X7 -dependent pore 
function alone can influence phenotype (Sorge eta!., 2012). 
However, at present, there are not any FDA-approved drugs 
that selectively target downstream P2X7 signaling and not ion 
channel activation. Therefore, NRTis could be valuable both 15 
clinically and experimentally in the selective targeting of 
P2X7 function. 
10 embodiments, d4T inhibits inflammasome activation by Alu 
RNA. Indeed, Alu RNA causes NLRP3 inflammasome acti-
vation, which is marked by processing of the enzyme Caspase 
1, and FIG. 5 provides a Western blot showing thatAlu RNA 
causes Caspase-1 maturation in primary human RPE cells at 
24 hours after Alu administration (Top, Lane 2, lower band), 
which is blocked by co-treatment with d4T (1 00 uM; Lane 3). 
The bottom row in FIG. 5 is a vinculin loading control. 
In certain embodiments, 3TC inhibits inflarnmasome acti-
vation by Alu RNA. Indeed, Alu RNA causes NLRP3 inflam-
20 masome activation, which is marked by processing of the 
enzyme Caspase 1. FIG. 6 is a Western blot showing thatAlu 
RNA causes Caspase-1 maturation in primary human RPE 
cells at 24 hours after Alu administration (top, lane 2, lower 
band), which is blocked with co-treatment with 3 TC (20-1 00 
A role for P2X7 in regulating HIV replication was recently 
proposed (Hazleton et a!., 2012), and HIV patients have 
increased plasma IL-lS levels (Ahmad eta!., 2002; Iannello 
eta!., 201 0), which decrease after treatment with NRTI-con-
taining highly active anti-retroviral therapy (Stylianou eta!., 
2003 ). Notably, reduction of plasma IL-18 levels by NRTI 
treatment of HIV-1 infected patients did not significantly 
associate with viral load or CD4+ T-cell counts (David et a!., 
2000), indicating that NRTis can dampen IL-18 levels before 
inhibition of viral replication occurs. IL-18 maturation 
requires pro-ILlS cleavage by active Caspase 1, which typi-
cally also requires P2X7 activation. Thus, the methods and 
experiments of the present disclosure are consistent with the 30 
idea that NRTis can modulate HIV-induced cytokine expres-
sion independent of reverse transcriptase inhibition. 
25 uM; lane 3). On the bottom, the loading control, vinculin, is 
visible. 
Next, FIG. 7 provides evidence of AZT, cordycepin, and 
abacavir inhibition of inflammasome activation by Alu RNA. 
Indeed, Alu RNA causes NLRP3 inflammasome activation, 
which is marked by processing of the enzyme Caspase 1. FIG. 
7 is a Western blot showing that Alu RNA causes Caspase-1 
In some embodiments, d4T prevents RPE degeneration 
induced by Alu RNA in wild type mice. As shown in FIG. 1, 
sub-retinal Alu RNA administration to mice causes RPE 35 
maturation in primary human RPE cells at 24 hours after Alu 
administration (top, lane 2, lower band), which is blocked 
with co-treatment with azidothymidine (AZT), cordycepin, 
and abacavir (ABC) (50-100 uM; Lanes 3-8). Again, the 
loading control vinculin is shown on the bottom. degeneration in a mouse model of age-related macular degen-
eration. Indeed, as shown, d4T co-delivered to the vitreous 
humor of wild type mice prevents Alu RNA-induced RPE cell 
death in a dose-dependent manner at one week after delivery. 
The top row of FIG. 1 provides an ocular fundus photograph 
of mice receiving control PBS, or Alu RNA treatment, with or 
without increasing amounts of d4T (left to right). Arrows 
denote depigmented regions ofRPE cell death, which resolve 
at highest dose of d4T. The bottom row of FIG. 1 shows an 
RPE flat mount, stained for intercellular junctions (Z0-1) in 
red that are disrupted upon Alu RNA administration, but 
restored to healthy RPE morphology/intercellular junctions 
at highest dose of d4 T. 
In certain embodiments, the present disclosure provides 
that d4T inhibits inflammasome activation by LPS/ATP. As 
such, FIG. 8 provides a gel showing that primary human RPE 
40 cells treated with LPS/ ATP, a classic inflammasome activator, 
exhibit increased Casp-1 activation, and phosphorylation of 
IRAK4, which is also a marker of inflammasome signaling 
via the cell surface receptor adaptor protein MyD88. More-
over, as shown in FIG. 8, d4T (25/100 uM) blocks Casp-1 
45 activation and IRAK 4 phosphorylation induced by LPS/ ATP. 
The loading control in FIG. 8 is vinculin. Furthermore, as 
shown, LPS andATP activate the NLRP3 inflammasome only 
in combination, thus treatment with one or the other alone is 
Meanwhile, in certain embodiments, d4T protects against 
cytotoxicity induced by plasmid expressingAlu RNA in vitro. 50 
FIG. 2 shows that human (HeLa) cells treated with an 
enforced expression plasmid for Alu RNA (pAluA) for 
denoted amounts of time exhibited profoundly reduced 
viability compared to a null plasmid (pUC19), as monitored 
useful as a control for this experiment. 
The present disclosure further provides that, in exemplary 
embodiments, d4T and other NRTis reduce inflarnmasome 
activation byLPS/ATP.AspresentedinFIG. 9, d4T, 3TC, and 
cordycepin (at 100 uM), all di-deoxy nucleoside reverse tran-
scriptase inhibitors, inhibit Caspase-1 activation (active p20 
by MTS proliferation assay, and that d4T co-administration 
prevented cell death induced by Alu overexpression. 
In some exemplary embodiments, d4T does not rescue 
cytotoxicity via reduction inAlu RNA levels. As presented in 
FIG. 3, primary human RPE cells treated with antisense oli-
gonucleotides targeting DICERl (Dcr as) (lane 3 (third lane 
from left)) show increased Alu RNA levels in the nuclear 
compartment compared to control antisense oligonucleotides 
(Ctr as) (lane 1 (leftmost)), monitored by Northern blotting 
using an Alu-specific probe. Meanwhile, co-administration 
ofd4T (lanes 2 and 4) does notreduceAlu RNA levels. FIG. 
3 shows u6 (bottom row) as a loading control for nuclear 
fraction. 
55 band, top) and IL-18 maturation (bottom) induced by LPS/ 
ATP. To produce FIG. 9, cell culture supernatants were col-
lected after (i) no treatment, (ii) LPS treatment, or (iii) LPS/ 
ATP treatment of mouse bone marrow-derived macrophages 
and run on Western blotting probing with antibodies for 
60 Caspase-1 and IL-18. 
In some embodiments of the present disclosure, d4T inhib-
its nigericin-induced inflammasome activation. Per FIG. 10, 
d4T (1 00, 250 uM) inhibits IL-l beta maturation (top, 18 and 
22 kDa forms) and Caspase-1 activation (active p20 band, 
65 bottom) induced by nigericin. Cell culture supernatants were 
collected after (i) no treatment, (ii) LPS treatment, or (iii) 
LPS/nigericin treatment of mouse bone marrow-derivedmac-
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rophages, and run on Western blotting probing with antibod-
ies foriL-1 beta and Caspase-1. FIG. 10 shows the results of 
these efforts. 
22 
Additionally, in some embodiments, d4T does not inhibit 
IL-l beta secretion from PMA-differentiated THP-1 mono- 5 
Furthermore, it has been shown that d4T reduces extracel-
lular potassium levels that increase after Alu RNA transfec-
tion. (FIG. 18) Indeed, cell culture potassium levels increase 
in primary human RPE cells treated with Alu RNA for 6 
hours, an effect that is reduced by d4T co-administration. For 
FIG. 18, potassium levels were determined in cell culture cytes induced by MSU. Human THP-1 monocytes were dif-
ferentiated into macrophages with PMA. As shown in FIG. 
11, treatment with monosodium urate (MSU), a known 
inflammasome activator, increased IL-l beta secretion com-
pared to non-treated cells, whereas d4T co-administration at 
a range of doses (25-1000 uM) did not significantly affect 
IL-l beta secretion. Further, d4T does not block MSU-in-
duced IL-l beta secretion as determined by ELISA (n=3-4). 
supernatants spectrophotometrically using a potassium-de-
pendent pyruvate kinase assay. 
Next, in some embodiments, d4T blocks bzATP-induced 
10 
cell permeability to Yo-Pro! (P2X7 receptor assay), as shown 
in FIG. 19. d4T blocked YO-PRO-I iodide entry in HEK293 
cells stably expressing the human P2X7 receptor stimulated 
with the P2X7 -selective agonist bzATP. Cells were pre-incu-In certain embodiments, d4T and other nucleoside reverse 
transcriptase inhibitors do not inhibit IL-l beta secretion from 
PMA-differentiated THP-1 monocytes induced by MSU. To 
illustrate this, human THP-1 monocytes were differentiated 
into macrophages with PMA. Treatment with MSU increased 
IL-l beta secretion compared to non-treated cells. (FIG. 12) 
Meanwhile d4T, 3TC, or cordycepin (all are di-deoxy nucle- 20 
otide analogs) co-administration at a range of doses (25-1 000 
uM) did not significantly affect IL-l beta secretion, as shown 
15 bated with d4T for 30 minutes prior to addition of bzATP/ 
YO-PRO, and fluorescence at 4S5/515 nm measured at t=30 
minutes. 
Moreover, d4T blocks Alu-induced RPE degeneration and 
Caspase-1 activation independent of reverse transcriptase 
inhibition. 
In some embodiments, the present disclosure is directed to 
a compound having the structure(s) provided in FIG. 20. FIG. 
20 includes a chemical structure of methoxy-d4 T (me-d4 T) 
and of d4T. As shown in FIG. 20, a single substitution of the 
in FIG.12. 
Next, in some embodiments, d4T reduces NLRP3 priming 
induced by Alu RNA. Indeed, as provided in the bar graph of 
FIG. 13, Alu RNA transfection increases NLRP3 mRNA 
levels in primary human RPE cells at 16 hours, an event 
termed "priming" (Y-axis) compared to mock (transfection 
reagent alone). This effect is blunted by co-administration of 
d4 T (1 00 uM) and normalized to ISS RNA control. 
Furthermore, in exemplary embodiments of the present 
disclosure, d4T reduces IL-l beta priming induced by Alu 
RNA. FIG. 14 illustrates thatA!u RNA transfection increases 
IL-l beta mRNA levels in primary human RPE cells at 24 
hours, an event termed "priming", (Y-axis) compared to mock 
(transfection reagent alone). This effect is blunted by co-
administration of d4T (100 uM) and normalized to ISS RNA 
control. 
Meanwhile, in some embodiments, d4T reduces mitochon-
drial ROS caused by Alu expression. FIG. 15 demonstrates 
that enforced expression of Alu (pA!uA) causes increased 
mitochondrial reactive oxygen species (mtROS), as detected 
25 ribose 5' hydroxyl group with a methoxy group (circled) has 
been designed by the inventors of the present disclosure to 
prevent d4T phosphorylation. Accordingly, in some embodi-
ments, the present disclosure is directed to a compound com-
prising a single substitution of a ribose 5' hydroxyl group with 
30 a methoxy group. And, in some embodiments, the present 
disclosure provides compounds comprising a methoxy group 
in place of a ribose 5' hydroxyl group for preventing phos-
phorylation, such as d4T phosphorylation. 
The present disclosure further provides the results of addi-
35 tiona! experiments in FIG. 21-FIG. 23. Indeed, FIG. 21 is a 
Western blot ofCaspase-1 activation (p20 subunit) in primary 
human RPE cells transfected with Alu RNA±me-d4T; FIG. 
22 shows cells, wherein unmodified d4T, but not me-d4T, 
blocks replication of a GFP-expressing lentivirus in HeLa 
40 cells; and FIG. 23 provides a graph illustrating that unmodi-
fied d4T, but not me-d4T, reduces mtDNA levels (normalized 
to chromosomal DNA ex on-intron junction sequence) in pri-
mary mouse RPE cells as determined by real-time quantita-by MitoSox assay. In order to produce FIG. 15, primary 
human RPE cells were incubated with Alu expressing plas-
mid or control plasmid(pUC19)withorwithout d4T.After 15 45 
hours cells were co-stained for mtROS (red) and for cell 
count, nuclei (blue; Hoechst DNA stain). Cells in the pA!uA 
group exhibited greater mtROS staining (red) compared to 
pUC19 control, an effect that is reduced in pAluA+d4T 
treated cells. 
tive PCR. n=4, *p<0.05 by Student's t-test. 
In some embodiments, it has been shown that Me-d4T 
(intraperitoneal injection) prevents Alu-induced RPE degen-
eration in mice. FIG. 24, top row, provides flat mounts stained 
for zonula occludens-1 (Z0-1; red), bottom row. Degenera-
tion is outlined if FIG. 24 by blue arrowheads. Representative 
50 images of n=4 are shown. 
And in further embodiments, d4T does not inhibit ATP 
release induced by Alu RNA. (FIG. 16) Primary human RPE 
cells treated with Alu RNA for the times indicated release 
ATP. To provide FIG. 16, cell culture supernatant was col-
lected from mock or Alu RNA treated cells, with or without 
d4T. ATP was detected using an ATP-dependent luciferase 
assay. And, notably, d4T did not affect ATP release. 
In certain embodiments, d4T reduces ATP-induced cell 
permeability to Yo-Pro! (P2X7 receptor assay), as shown in 
FIG. 17. To prepare FIG. 17, THP-1 cells differentiated into 
macrophages by PMA allowed entry of the large fluorescent 
dye Yo-Pro 1, in an assay for P2X7 receptor activity. It was 
observed that d4T dose-dependently reduced Yo-Pro entry 
induced by ATP, determined by an area -scan fluorescent mea-
surement in a 96 well microplate reader. Indeed, FIG. 17 
provides the results of the fluorescence measurement in rela-
tive fluorescence units (RFU, y-axis ). 
Meanwhile, FIG. 25 provides a schematic overview of 
me-d4T synthesis, and FIG. 26 is an HPLC chromatogram of 
me-d4T (peak #6) final product, >97% purity. And FIG. 27 is 
a lH NMR spectroscopy of me-d4T final product, wherein 
55 the chemical shifts are consistent with the structure, and FIG. 
28 provides the results ofliquid chromatography/mass spec-
trometry of me-d4T final product, m/z ratio consistent with 
the structure. 
FIG. 29, FIG. 30 and FIG. 31 provide for methoxy variants 
60 of nucleoside analogs. Specifically, FIG. 29 shows the chemi-
cal structure of3TC (2'3' dideoxycytidine ); FIG. 30 provides 
the chemical structure of AZT (3'-azido-2',3'-dideoxythymi-
dine); and FIG. 31 shows the chemical structure of ABC 
(cyclopropylaminopurinylcyclopentene). In each of FIGS. 
65 29-31, the methoxy variation (0-methyl group) of nucleoside 
analog is circled. Further, FIG. 32 shows a cell permeant 
variant of d4T (IC-d4T), where "n" group is equal to 11. 
US 9,326,983 B2 
23 
Derivatives include cell permeant variants of 3TC, AZT, 
ABC, where the nucleobase group (circled) may be replaced, 
24 
FIGS. 51-54 show that, in some exemplary embodiments, 
P2X7-dependent pore function mediates Alu-induced 
Caspase-1 activation. Indeed, FIG. 51 is a Western blot of 
Caspase-1 activation (p20 subunit) in primary human RPE 
in various embodiments, by 3TC, AZT, ABC, or methoxy-
variants ofd4T, 3TC,AZT,ABC (FIG. 29-31), or derivatives 
thereof. 
Meanwhile, FIG. 33 provides the chemical structure of an 
exemplary NRTI according to the present disclosure. 
In certain embodiments, the present disclosure provides 
that NRTis block Alu-induced RPE degeneration and/or 
Caspase-1 activation. For example, FIG. 34 shows a Western 
blot ofCaspase-1 activation (p20 subunit) and IRAK4 phos-
phorylation in primary human RPE cells transfected withA!u 
RNA±d4T. FIG. 35 is a Western blot ofCaspase-1 activation 
5 cells transfected withA!u RNA, with short peptide (Panxl 10), 
which blocks P2X7 pore function but not cation flux (vs. 
scrambled peptide: Scr Panxl 10); FIG. 52 is a Western blot of 
Caspase-1 activation (p20 subunit) in primary human RPE 
cells transfected withA!u RNA, with calmidazolium (FIG. 32 
10 provides the chemical structure of IC- and EC-d4T used), 
which blocks P2X7 cation flux but not pore function; and 
FIG. 53 is a Western blot of Caspase-1 activation (p20 sub-
unit) in primary human RPE cells transfected withA!u RNA, in human RPE cells transfected withA!u RNA±NRTis (3TC, 
AZT, ABC). FIG. 36 shows that pA!u causes RPE degenera-
tion, which is prevented by oral administration of d4T, and 
FIG. 37 shows that pA!u causes RPE degeneration, which is 
prevented by intraperitoneal administration of AZT. FIG. 36 
and FIG. 37 include fundus photographs: top row; flat mounts 
stained for zonula occludens-1 (Z0-1; red), bottom row. 
Degeneration is outlined by blue arrowheads. Scale bars, 50 
flill. 
15 with cell permeable (I C), cell-impermeable (EC), or unmodi-
fied (no tag) d4T. Furthermore, FIG. 54 shows that d4T pre-
vents pAin-induced mitochondrial ROS generation in pri-
mary human RPE cells. In FIG. 54, mitochondrial reactive 
oxygen species (ROS) were visualized with MitoSox (Red) 
20 and cell nuclei with Hoechst (Blue). 
One of ordinary skill in the art will recognize that addi-
tional embodiments or implementations are possible without 
departing from the teachings of the present disclosure or the 
scope of the claims which follow. This detailed description, 
FIGS. 38-41 illustrate that NRTis block LPS/ ATP-induced 
inflammasome activation. FIGS. 38 and 39 show that d4T 
blocked Caspase-1 (FIG. 38) and IL-l beta (FIG. 39) activa-
tion in LPS/ ATP treated primary mouse bone marrow -derived 
macrophages as determined by western blot of cell culture 
media and lysate. Moreover, FIG. 40 presents chromatograms 
showing that Raji TK+ cells, but not Raji TK- cells, phospho-
rylate AZT to AZT-triphosphate (AZT-TP) as determined by 
liquid chromatography-mass spectrometry (LC-MS). And 
FIG. 41 shows that AZT blocks IL-l beta activation by LPS/ 
ATP in both Raji TK- and TK+ cells as determined by western 
blot of celllysates. Representative images of n=3-4 experi-
ments are provided in each of FIGS. 38-41. 
25 and particularly the specific details of the exemplary embodi-
ments and implementations disclosed herein, is given prima-
rily for clarity of understanding, and no unnecessary limita-
tions are to be understood therefrom, for modifications will 
become obvious to those skilled in the art upon reading this 
30 disclosure and may be made without departing from the spirit 
or scope of the claimed invention. 
35 
In some embodiments, the present disclosure provides that 
NRTis selectively block P2X7 pore function and P2X7-
driven models of graft rejection and sterile liver inflamma-
tion, as shown in FIGS. 42-43. FIG. 42 is a bar graph illus-
trating that d4T does not blockA!u-inducedATP release from 40 
primary human RPE cells (n=4). Meanwhile, FIG. 43 is a 
graph illustration showing that NRTis selectively block P2X7 
pore function and P2X7-driven models of graft rejection and 
sterile liver inflarmnation, providing a graph of the fluores-
cence(% ofbzATP) over time (minutes). 45 
And in certain exemplary embodiments, the present dis-
closure provides that d4T blocks Caspase-1 activation with-
out reducing Alu RNA levels. Accordingly, FIG. 44 provides 
a 
Western blot of Caspase-1 activation (p20 subunit) and 50 
IRAK4 phosphorylation in primary mouse RPE cells trans-
fected withA!u RNA±d4T.And FIG. 45 presents a Northern 
blot of biotin-UTP-labeled Alu RNA-transfected primary 
humanRPE cells. Notably, in FIG. 45, d4T didnotreduceA!u 
RNA levels (normalized to u6 RNA). 55 
Next, FIGS. 46-47 provide LC-MS/MS spectra of AZT-
triphosphate (AZT-TP, target compound; FIG. 46) andAZU-
triphosphate (AZU-TP, internal standard; FIG. 47). And 
FIGS. 48-49 show the chromatographic separation of Raji 
TK- cells spiked withAZT-TP (FIG. 48) andAZU-TP (FIG. 60 
49) with MS spectra (insets) to confirm identity of designated 
peaks. 
FIG. 50 is a standard curve of AZT-TP standards (black 
circle). Raji TK+ samples treated with AZT produced AZT-
TP (white triangles), whereas AZT-TP was not detectable in 65 
Raji TK- cells treated withAZT. FIG. 50 is representative of 
two experiments. 
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28 
(ii) a compound having the structure of 
or a pharmaceutically acceptable salt thereof; 
(iii) stavudine (d4T); 
(iv) lamivudine (3TC); 
(v) cordycepin; 
(vi) azidothymidine (AZT); 
(vii) abacavir (ABC); and 
(viii) a combination thereof. 
2. The method of claim 1, comprising inhibiting inflam-
masome activation by Alu RNA associated with a cell. 
3. The method of claim 2, wherein the cell is a retinal 
pigmented epithelium cell, a retinal photoreceptor cell, a 
choroidal cell, or a combination thereof. 
All publications, patents, and patent applications men-
tioned in this specification are herein incorporated by refer-
ence to the same extent as if each individual publication, 
patent, or patent application was specifically and individually 4. The method of claim 1, comprising reducing ATP-in-indicated to be incorporated by reference. 
35 duced permeability of a cell. 
It will be understood that various details of the presently s. The method of claim 4, wherein the cell is a retinal 
disclosed subject matter can be changed without departing pigmented epithelium cell, a retinal photoreceptor cell, a 
from the scope of the subject matter disclosed herein. Fur- choroidal cell, or a combination thereof. 
thermore, the foregoing description is for the purpose of 
illustration only, and not for the purpose oflimitation. 40 6. The method of claim 1, comprising reducing an amount 
of mitochondrial reactive oxygen species in a cell. 
What is claimed is: 
1. A method for treating retinal degeneration, comprising: 
administering an effective amount of a composition to a 45 
subject in need of treatment for retinal degeneration, 
wherein the composition comprises a reverse transcriptase 
inhibitor selected from: 
(i) a compound having the structure of 
or a pharmaceutically acceptable salt thereof; 
50 
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7. The method of claim 1, comprising inhibiting activation 
of at least one inflammasome in a subject's eye. 
8. The method of claim 7, wherein the at least one inflam-
masome is selected from an NLRP3 inflammasome, an IL-l 
beta inflammasome, and a combination thereof. 
9. The method of claim 1, wherein the composition com-
prises a pharmaceutically acceptable carrier. 
10. A compound having the structure 
or a pharmaceutically acceptable salt thereof. 
US 9,326,983 B2 
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11. A pharmaceutical composition comprising the com-
pound of claim 10 and a pharmaceutically acceptable carrier. 
12. A compound having the structure 
or a pharmaceutically acceptable salt thereof. 
10 
15 
20 
13. A pharmaceutical composition comprising the com-
pound of claim 12 and a pharmaceutically acceptable carrier. 
14.Amethod for treating retinal degeneration, comprising: 
administering an effective amount of a composition to a 25 
subject in need of treatment for retinal degeneration, 
wherein the composition comprises: 
(i) a compound having the structure of 
30 
35 
40 
or a pharmaceutically acceptable salt thereof; or 
30 
(ii) a compound having the structure of 
or a pharmaceutically acceptable salt thereof. 
15. The method of claim 14, wherein the composition 
further comprises: stavudine (d4T), lamivudine (3TC), 
cordycepin, azidothymidine (AZT), abacavir (ABC), or a 
combination thereof. 
16. The method of claim 14, comprising inhibiting inflam-
masome activation by Alu RNA associated with a cell. 
17. The method of claim 16, wherein the cell is a retinal 
pigmented epithelium cell, a retinal photoreceptor cell, a 
choroidal cell, or a combination thereof. 
18. The method of claim 14, comprising reducing ATP-
induced permeability of a cell. 
19. The method of claim 18, wherein the cell is a retinal 
pigmented epithelium cell, a retinal photoreceptor cell, a 
choroidal cell, or a combination thereof. 
20. The method of claim 14, comprising reducing an 
amount of mitochondrial reactive oxygen species in a cell. 
21. The method of claim 14, comprising inhibiting activa-
tion of at least one inflmasome in a subject's eye. 
22. The method of claim 21, wherein the at least one 
inflammasome is selected from an NLRP3 inflmasome, an 
IL-l beta inflammasome, and a combination thereof. 
23. The method of claim 14, wherein the composition 
comprises a pharmaceutically acceptable carrier. 
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